Isfahan University
Also known as: Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran | Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran | Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute | Department of Neurology, School of Medicine, Isfahan University of Medical Sciences | Department of oral and maxillofacial surgery, Faculty of Dentistry, Isfahan University of Medical Sciences | Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran | Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran. | Isfahan MS Society, Isfahan University of Medical Sciences, Isfahan, Iran | Isfahan University, Isfahan, Iran | Isfahan University of Medical Sciences | Isfahan University of Medical Sciences, moayedi@med.mui.ac.ir | Isfahan University of Medical Sciences, School of Health | Leila Dehghani | Mohammad Javad Shirani | Pediatric Nephrologist,Isfahan University, Isfahan, Iran | Physiology Research Center,Isfahan University of Medical Sciences | Saeed Abbasi | Seyed Mehdi Pourafzali | University of Isfahan
Highest phase reached
Phase 4
First clinical trial
Apr 1, 2001Last known activity
Feb 1, 2025
Timeline
1940s
- Jan 1, 1946
Isfahan University— Founded
Drugs by trial phase (209 distinct, 235 trials)
Phase 4 (50 own, 0 via acquisition)
Phase 3 (81 own, 0 via acquisition)
Phase 2 (45 own, 0 via acquisition)
Phase 1 (11 own, 0 via acquisition)
Other trials (22 own, 0 via acquisition)
Indications
Studied for
- Acute Coronary Syndrome
- Acute Kidney Injury
- Acute Pain
- Agnosia
- Amyotrophic Lateral Sclerosis
- Appendicitis
- Asthma
- Asthma, Aspirin-Induced
- Atherosclerosis
- Atrial Fibrillation
- Atrophy
- Attention Deficit Disorder with Hyperactivity
- Behcet Syndrome
- beta-Thalassemia
- Blepharitis
- Blood Loss, Surgical
- Brain Injuries
- Brain Injuries, Traumatic
- Breast Neoplasms
- Cardiovascular Diseases
- Cerebrovascular Disorders
- Cholangitis
- Cholangitis, Sclerosing
- Chronic Periodontitis
- Colic
- Coronary Artery Disease
- Cough
- Depression
- Depressive Disorder
- Dermatitis
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Diabetic Retinopathy
- Diarrhea
- Disease
- Dissociative Disorders
- Drug Overdose
- Dyslipidemias
- Dyspepsia
- Dysphonia
- Edema
- Emergencies
- Essential Hypertension
- Eye Diseases
- Fatigue
- Fatty Liver
- Fetal Growth Retardation
- Fibrosis
- Foot Diseases
- Fractures, Multiple
- Gastroesophageal Reflux
- Graves Ophthalmopathy
- Headache
- Head and Neck Neoplasms
- Heart Diseases
- Heart Failure
- Hemophilia A
- Hemorrhage
- Hepatitis
- Hepatitis A
- Hepatitis, Autoimmune
- Hepatitis C
- Hepatitis C, Chronic
- Hernia
- Hoarseness
- Hyperkinesis
- Hyperlipidemias
- Hypospadias
- Hypotension
- Hypothyroidism
- Infarction
- Infertility
- Infertility, Female
- Inflammation
- Insulin Resistance
- Iron Overload
- Irritable Bowel Syndrome
- Ischemia
- Keratoconus
- Kidney Diseases
- Kidney Failure, Chronic
- Laryngeal Neoplasms
- Leishmaniasis
- Leishmaniasis, Cutaneous
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lichen Planus
- Lichen Planus, Oral
- Lipid Metabolism Disorders
- Liver Cirrhosis
- Liver Diseases
- Macular Edema
- Major Depressive Disorder
- Meniere Disease
- Metabolic Diseases
- Migraine Disorders
Recent trials (50)
- NCT06809751Sponsor investigatorPhase 2/Phase 3Feb 1, 2025
- NCT06809751OfficialPhase 2/Phase 3Feb 1, 2025
- NCT06809751Lead sponsorPhase 2/Phase 3Feb 1, 2025
- NCT06642363OfficialPhase 1Jul 22, 2024
- NCT06642363Sponsor investigatorPhase 1Jul 22, 2024
- NCT06642363Lead sponsorPhase 1Jul 22, 2024
- NCT06379659Lead sponsorPhase 1/Phase 2May 1, 2024
- NCT06379659Sponsor investigatorPhase 1/Phase 2May 1, 2024
- NCT06466850Lead sponsorN/AJan 1, 2024
- NCT06466850OfficialN/AJan 1, 2024
- NCT06466850Sponsor investigatorN/AJan 1, 2024
- NCT05973253Lead sponsorPhase 2/Phase 3Apr 21, 2023
- NCT05973253Sponsor investigatorPhase 2/Phase 3Apr 21, 2023
- NCT05973253Reponsible party - principal investigatorPhase 2/Phase 3Apr 21, 2023
- NCT05578001Lead sponsorPhase 3Jul 1, 2022
Details
- Founded
- Isfahan, IR Jan 1, 1946
- Last known activity
- Feb 1, 2025